Skip to main content

Table 4 Pre- and post-study drug hematological and coagulation profile. Data are expressed as mean (SD), unless otherwise specified

From: Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial

  Prior to study drug Post-study drug
FEIBA
n = 6
Placebo
n = 6
FEIBA
n = 6
Placebo
n = 6
R value, min 7.78 (1.83) 6.63 (1.75) 5.5 (1.29) 5.17 (1.27)
K, min 2.34 (1.99) 2.35 (0.69) 2.58 (1.88) 2.12 (1.21)
α angle, degrees 66 (15) 61 (7) 65 (12) 63 (12)
MA, mm 53 (13) 55 (6) 55 (12) 60 (6)
A, mm 53 (12) 55 (5.2) 55 (13) 59 (5)
CI −2.3 (3.9) −1.6 (2.3) 0.32 (3.0) 0.17 (2.8)
LY 30 0.2 (0.3) 0.03 (0.1) 0.04 (0.05) 0.13 (0.33)
Hematocrit 27.3 (25.0) 27.7 (24.4) 28.6 (22.8) 29.7 (22.4)
Platelets 98 (60) 114 (25) 135 (67) 168 (40)
INR 2.2 (0.7) 1.8 (0.2) 1.38 (0.3) 1.50 (0.1)
aPTT 48 (23) 36 (10) 45 (15) 35 (5)
Fibrinogen 189 (117) 189 (53) 220 (104) 194 (43)
  1. FEIBA, factor eight inhibitor bypass activity; R, reaction time; K, coagulation time; MA, maximum amplitude; A, amplitude; CI, coagulation index; LY 30, amplitude at 30 min; INR, international normalized ratio; aPTT, activated partial thromboplastin time